Clinical Trial Search

Primary: Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b) — 0; 1; 2; 0 Participants with DLT

Primary: Amount of Preservation of Alveolar Ridge Dimensions i.e..,Clinical Horizontal Ridge Width Change in Millimeter as Result of Ridge Preservation Procedures — 2.54; 2.72…

Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970

Primary: Apparent Eradication of Nasal SA After the Last Dose of XF-73 Based on Semi-quantitative SA Scores From a Broth Enrichment Method. — 3; 1; 4 participants — p=0.792

Primary: Cumulative Summed Pain Intensity Difference (SPID+) — 4.6; 6.3; 6.7; 5.2 units on a scale

Primary: Percent Change From Baseline in Body Weight at Week 26 — -0.6; -4.1; -1.9; -7.5 Percent Change — p=<0.001

Primary: PSA Response Rate — 38; 23 participants

Primary: Undetectable PSA Rate — 42; 34 participants — p=0.16

Primary: Objective Response Rate (ORR) for Dose Expansion Population — 61.7 % of participants

Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941

Primary: Safety of Low-dose FK-506 in PAH — 8; 18; 9; 22 number of AEs

Primary: Error in the Total Volume Dispensed and Flow Rate — NA; -1.48; NA; -1.75 percentage of error

Primary: Phase 1: Determination of Maximum Tolerated Dose (MTD) First Without and Then With Administration of Prophylactic G-CSF. — 2; 3; 4; 5 mg/m2

Primary: Disease-free Survival (DFS) — 6; 3; 9; 4 participants

Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98